Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-28T00:45:56.990Z Has data issue: false hasContentIssue false
  • English
  • Français

Duration of Virus Shedding After Trivalent Intranasal Live Attenuated Influenza Vaccination in Adults

Published online by Cambridge University Press:  21 June 2016

Thomas R. Talbot ,
Deidre D. Crocker ,
Jody Peters ,
Jennifer K. Doersam ,
Mine R. Ikizler ,
Edith Sannella ,
Peter F. Wright  and
Kathryn M. Edwards
Thomas R. Talbot*
Affiliation:
Division of Infectious Diseases, Departments of Medicine and Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
Deidre D. Crocker
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Jody Peters
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Jennifer K. Doersam
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Mine R. Ikizler
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Edith Sannella
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Peter F. Wright
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
Kathryn M. Edwards
Affiliation:
Division of Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee Pediatric Clinical Research Office, Vanderbilt University School of Medicine, Nashville, Tennessee
*
A-2200 Medical Center North, 1161 21st Avenue South, Vanderbilt University Medical Center, Nashville, TN37232. [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To characterize the probability and duration of viral shedding among adults given trivalent live attenuated influenza vaccine (LATV).

Design:

Prospective surveillance study.

Methods:

Nasal wash samples were collected from adult volunteers at baseline and on days 3, 7, and 10 and between days 17 and 21 following intranasal LAIV vaccination. The presence, titer, and identification of each specific strain of influenza virus shed were determined by standard methodology.

Results:

Twenty subjects received LATV. No samples were positive for influenza virus at baseline. After LAIV vaccination, influenza virus was recovered from 10 of 20 vaccinees on day 3, from 1 of 18 vaccinees on day 7, and from none of the samples on days 10 or 17 through 21. Vaccinees who shed vaccine virus were significantly younger than those who did not (mean age, 26.4 vs 38.6 years; P < .01). Although the presence of specific mucosal immunoglobulin A to influenza B was associated with significantly less shedding of influenza B after vaccination (P = .02), associations of shedding with other measures of immunity were not detected.

Conclusion:

The duration of shedding of vaccine virus after LAIV in adults is limited and may be associated with an individual's prior influenza vaccination history.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 26 , Issue 5 , May 2005 , pp. 494 - 500
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bridgses, CB, Harper, SA, Fukuda, K, Uyeki, TM, Cox, NJ, Singleton, JA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1–34.Google Scholar
2.Harper, SA, Fukuda, K, Cox, NJ, Bridges, CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1–8.Google Scholar
3.Belshe, RB, Mendelman, PM, Treanor, J, et al.The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405–1412.CrossRefGoogle ScholarPubMed
4.Belshe, RB, Gruber, WC, Mendelman, PM, et al.Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the. vaccine. J Pediatr 2000;136:168–175.Google Scholar
5.Nichol, KL, Mendelman, PM, Mallon, KP, et al.Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137–144.Google Scholar
6.Medlmmune Vaccines, Inc. Influenza Virus Vaccine, Live Intranasal FluMist [package insert]. Gaithersburg, MD: Medlmmune Vaccines, Inc.; 2003.Google Scholar
7.Anonymous. Flu mystified: hospitals are in a fog. of live viral vaccine issues. Hospital Infection Control 2004;31:1–5.Google Scholar
8.Vesikari, T, Karvonen, A, Korhonen, T, et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility an. phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending da. care. Presented at th. 41st Annual Interscience Conference on Antimicrobial Agents an. Chemotherapy; December 16-19, 2001; Chicago, IL. Abstract G-450.Google Scholar
9.King, JC Jr, Treanor, J, Fast, PE, et al.Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181:725–728.CrossRefGoogle ScholarPubMed
10.Belshe, RB, Swierkosz, EM, Anderson, EL, Newman, FK, Nugent, SL, Maassab, HF. Immunization of infants and. young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine. J Infect Dis 1992;165:727–732.CrossRefGoogle ScholarPubMed
11.Keitei, WA, Couch, RB, Quarles, JM, Cate, TR, Baxter, B, Maassab, HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993;167:305–311.Google Scholar
12.Meguro, H, Bryant, JD, Torrence, AE, Wright, PF. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979;9:175–179.Google Scholar
13.Boyce, TG, Gruber, WC, Coleman-Dockery, SD, et al.Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999;18:82–88.Google Scholar
14.Snyder, MH, Banks, S, Murphy, BR. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26:2034–2040.Google Scholar
15.Hierholzer, JC, Suggs, MT. Standardized viral hemagglutination and hemagglutination-inhibition tests: I. Standardization of erythrocyte suspensions. Appl Microbiol 1969;18:816–823.Google Scholar
16.Hierholzer, JC, Suggs, MT, Hall, EC. Standardized viral hemagglutination and hemagglutination-inhibition tests: II. Description and statistical evaluation. Appl Microbiol 1969;18:824–833.Google Scholar
17.Crowe, JE Jr, Sannella, EC, Pfeiffer, S, et al.CD154 regulates primate humoral immunity to influenza. Am J Transplant 2003;3:680–688.Google Scholar
18.Plotkin, SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis. J 2001;20:63–75.Google Scholar
19.Treanor, J, Wright, PF. Immune correlates of protection against influenza in the. human challenge model. Dev Biol (Basel) 2003;115:97–104.Google ScholarPubMed
20.Keitei, WA, Couch, RB, Cate, TR, Six, HR, Baxter, BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1990;161:22–26.CrossRefGoogle Scholar
21.Clements, ML, Snyder, MH, Sears, SD, Maassab, HF, Murphy, BR. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990;161:869–877.Google Scholar
22.Sears, SD, Clements, ML, Betts, RF, Maassab, HF, Murphy, BR, Snyder, MH. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988;158:1209–1219.Google Scholar
23.Reeve, P, Pibermann, M, Bachmayer, H, et al.Studies in man with a cold-recombinant live influenza B virus vaccine. J Med Virol 1982;9:1–9.CrossRefGoogle ScholarPubMed
24.Mortiz, AJ, Kunz, C, Hofman, H, Liehl, E, Reeve, P, Maassab, HF. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus: II. Evaluation in adult volunteers. J Infect Dis 1980;142:857–860.CrossRefGoogle ScholarPubMed
25.King, JC Jr, Fast, PE, Zangwill, KM, et al.Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;20:1124–1131.Google Scholar
26.Gruber, WC, Belshe, RB, King, JC, et al.Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996;173:1313–1319.Google Scholar
27.Edwards, KM, King, JC, Steinhoff, MC, et al.Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991;163:740–745.CrossRefGoogle ScholarPubMed
28.Feldman, S, Wright, PF, Webster, RG, et al.Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus. J Infect Dis 1985;152:1212–1218.Google Scholar
29.Wright, PF, Okabe, N, McKee, KT Jr, Maassab, HF, Karzon, DT. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982;146:71–79.Google Scholar
30.Murphy, BR, Clements, ML, Tierney, EL, Black, RE, Stienberg, J, Chanock, RM. Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers. J Infect Dis 1985;152:225–229.Google Scholar
31.Cha, TA, Kao, K, Zhao, J, Fast, PE, Mendelman, PM, Arvin, A. Genotypie stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000;38:839–845.Google Scholar
32.Belshe, RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177–185.Google Scholar
33.Gruber, WC, Hinson, HP, Holland, KL, Thompson, JM, Reed, GW, Wright, PF. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993;168:1282–1285.Google Scholar
34.Sendi, P, Locher, R, Bucheli, B, Battegay, M. Intranasal influenza vaccine in a working population. Clin Infect Dis 2004;38:974–980.Google Scholar
35.Harper, SA, Fukuda, K, Uyeki, TM, Cox, NJ, Bridges, CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1–40.Google Scholar